Written by: Joshua Nubla, PharmD, NCODA Download Here Description: The purpose of this PQI is to help provide awareness of larotrectinib and educate on management techniques. Background: Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that: Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired […]

Cazenovia, NY – NCODA, Inc. is pleased to announce its collaboration with Evofem Biosciences to positively impact the quality of life for female patients undergoing treatment, those recovering from cancer, and survivors by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate). […]

FOR IMMEDIATE RELEASE February 8, 2021 NCODA Welcomes Five New Executive Council Members Cazenovia, NY – NCODA, Inc. is pleased to announce the addition of five new members to the Executive Council. Paul Chadwick (Florida Cancer Specialists & Research Institute), Lucio Gordan, MD (Florida Cancer Specialists & Research Institute), Benjamin Lowentritt, MD (Chesapeake Urology), Stacey […]

SAN DIEGO, Feb. 4, 2021 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), a premier educational platform for community and academic oncology practices nationwide, are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and […]

Exelixis is pleased to announce the FDA approval of its first combination therapy–CABOMETYX + OPDIVO–for the first-line treatment of patients with advanced renal cell carcinoma (aRCC).1 This new approval in aRCC is supported by clinical data from the CheckMate-9ER trial. The major efficacy outcome measure was PFS.* Additional efficacy outcome measures were OS and ORR.* […]

Daiichi Sankyo and AstraZeneca are excited to announce that ENHERTU® (fam-trastuzumab deruxtecan-nxki) is now approved for a new indication. ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate that was recently approved for use in adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based […]

Accelerated approval of DARZALEX FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of […]

FOR IMMEDIATE RELEASE December 23, 2020   STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone | NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org www.ncoda.org MOST FAVORED NATION: TEMPORARY RESTRAINING ORDER ISSUED NCODA has been in opposition of the Most Favored Nation (MFN) model for Medicare patients since it was announced late […]

FOR IMMEDIATE RELEASE December 18, 2020 STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone, NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org https://www.ncoda.org MOST FAVORED NATION MODEL: NOT THE ANSWER FOR PATIENTS NCODA is in opposition of the Most Favored Nation (MFN) model for Medicare patients that would negatively affect patient access […]

Written by: Houston Holmes, MD, Texas Oncology Download Here Positive Quality Intervention: Tazemetostat (Tazverik®) management in Relapsed/Refractory Follicular Lymphoma  Description: This PQI will discuss the initiation and management of tazemetostat in the treatment of relapsed or refractory (r/r) follicular lymphoma (FL) Background: Tazemetostat is a methyltransferase inhibitor indicated for the treatment of adults and pediatric […]

FOR IMMEDIATE RELEASE December 11, 2020 STATEMENT FROM EXECUTIVE DIRECTOR: MICHAEL REFF Contact: Kevin Scorsone, NCODA Legislative & Policy Liaison Phone: (919) 903-2057 Email: kevin.scorsone@ncoda.org https://www.ncoda.org SUPREME COURT RULES UNANIMOUS: REGULATES PHARMACY BENEFIT MANAGERS Decision confirms that states will have the right to regulate; brings clarity and optimism Yesterday, December 10, 2020, the United States […]

MISSION STATEMENT/PHILOSOPHY: Our Mission Helping people live the healthiest lives possible® Our Vision Be a model health system by providing extraordinary care and superior service at an affordable cost. LOCATION(S): MEDICAL ONCOLOGY Offices 3131 La Canada Street, Ste 140 Las Vegas, NV 89169 (702) 735-7154 (702) 735-7153 Fax   2650  Tenaya Way, Ste 201 Las […]